Biomarkers for neurodegenerative diseases
O Hansson - Nature medicine, 2021 - nature.com
Biomarkers for neurodegenerative diseases are needed to improve the diagnostic workup
in the clinic but also to facilitate the development and monitoring of effective disease-…
in the clinic but also to facilitate the development and monitoring of effective disease-…
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation
For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but
recent results have shown that they could become a reality. Convincing data generated with …
recent results have shown that they could become a reality. Convincing data generated with …
Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers
The diagnosis of Alzheimer's disease can be improved by the use of biological measures.
Biomarkers of functional impairment, neuronal loss, and protein deposition that can be …
Biomarkers of functional impairment, neuronal loss, and protein deposition that can be …
Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables
…, E Lindholm, O Melander, O Hansson… - The lancet Diabetes & …, 2018 - thelancet.com
Background Diabetes is presently classified into two main forms, type 1 and type 2 diabetes,
but type 2 diabetes in particular is highly heterogeneous. A refined classification could …
but type 2 diabetes in particular is highly heterogeneous. A refined classification could …
[HTML][HTML] Two randomized phase 3 studies of aducanumab in early Alzheimer's disease
Background Alzheimer’s disease is a progressive, irreversible, and fatal disease for which
accumulation of amyloid beta is thought to play a key role in pathogenesis. Aducanumab is a …
accumulation of amyloid beta is thought to play a key role in pathogenesis. Aducanumab is a …
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study
O Hansson, H Zetterberg, P Buchhave… - The Lancet …, 2006 - thelancet.com
Background Disease-modifying treatment strategies for Alzheimer's disease have led to an
urgent need for biomarkers to identify the disease at a very early stage. Here, we assess the …
urgent need for biomarkers to identify the disease at a very early stage. Here, we assess the …
Four distinct trajectories of tau deposition identified in Alzheimer's disease
Alzheimer’s disease (AD) is characterized by the spread of tau pathology throughout the
cerebral cortex. This spreading pattern was thought to be fairly consistent across individuals, …
cerebral cortex. This spreading pattern was thought to be fairly consistent across individuals, …
Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders
… Dr Hansson reported receiving grants from Roche, Biogen, and Pfizer and receiving nonfinancial
… Dr Hansson made the final decision to submit the manuscript to JAMA for publication. …
… Dr Hansson made the final decision to submit the manuscript to JAMA for publication. …
[HTML][HTML] Brain charts for the human lifespan
Over the past few decades, neuroimaging has become a ubiquitous tool in basic research
and clinical studies of the human brain. However, no reference standards currently exist to …
and clinical studies of the human brain. However, no reference standards currently exist to …
A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance
…, V Gudnason, G Hallmans, A Hamsten, O Hansson… - Nature …, 2012 - nature.com
Recent genome-wide association studies have described many loci implicated in type 2
diabetes (T2D) pathophysiology and β-cell dysfunction but have contributed little to the …
diabetes (T2D) pathophysiology and β-cell dysfunction but have contributed little to the …